← Back to headlines
Pfizer's Lyme Vaccine Study Misses Mark, Complicating Approval
A study on Pfizer's Lyme vaccine reportedly missed its mark, potentially complicating the drug's path to regulatory approval.
23 Mar, 18:12 — 23 Mar, 18:12
Sources
Showing 1 of 1 sources
